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Pawe∏ Derlatka, Anna Nasierowska-Guttmejer, Izabella Koz∏owicz-Gudziƒska
I n t r o d u c t i o n.  Vulvar cancer is the fourth most common gynaecological malignancy, the treatment results of which still
remain unsatisfactory. The poor outcome is probably due to advanced stages of the disease at diagnosis and/or from delays in
the onset of complementary therapy which is necessary in case of the presence of lymph node metastases. These delays are, in
turn, usually caused by complications brought on by extensive surgical excision.
A i m.  Our aim was to conduct a pilot study in order to design an optimal method of sentinel lymph node identification in
patients with squamous cell carcinoma of the vulva and to assess the diagnostic value of the sentinel lymph node biopsy in this
particular malignancy.
M a t e r i a l  a n d  m e t h o d s.  The patients were considered as eligible for the study if they were to undergo radical vulvectomy
due to squamous cell carcinoma stage T1-2, N0-2, M0. The sentinel lymph node was identified intraoperatively using
a combined method: lymphoscintigraphy (gamma-camera scanning after the administration of Technetium Tc99m) and
Patentblau V staining.
R e s u l t s.  All the specimens were referred for histopathological examination as the lymph nodes were found to contain
lymphatic tissue. The positive prognostic value of simultaneous application of both methods of sentinel lymph node
identification was found to be 94.8%. Lymph node metastases were found in 13 cases out of a total of 40 operated inguinal
basins. In 3 cases metastases were found in the sentinel nodes, while the remaining unilateral lymphatic nodes were cancer-
free. We found no case of inguinal lymph node metastases in which the sentinel lymph node would be free of cancer
metastases.
C o n c l u s i o n s.  It may be assumed that the combination of lymphoscintigraphy and Patentblau dying is an effective
method of sentinel lymph node identification. In order to assess the diagnostic value of sentinel lymph node biopsy in the
treatment of squamous cell carcinoma of the vulva it is necessary to study a larger group of patients over a longer follow-up
period.
Identyfikacja i ocena wartoÊci diagnostycznej w´z∏a wartowniczego w raku p∏askonab∏onkowym sromu
w oparciu o doÊwiadczenia w∏asne
W s t ´ p.  Rak sromu jest IV co do cz´stoÊci wyst´powania lokalizacjà nowotworu z∏oÊliwego kobiecych narzàdów p∏ciowych.
Wyniki leczenia sà niezadawalajàce. Powodem niepowodzeƒ terapii mogà byç: cz´sto wysokie zaawansowanie choroby lub
opóênienie rozpocz´cia leczenia uzupe∏niajàcego u chorych z przerzutami do w´z∏ów ch∏onnych. Ten fakt jest zazwyczaj
spowodowany powik∏aniami, b´dàcymi rezultatem rozleg∏ego zabiegu operacyjnego.
C e l.  Celem pracy jest przeprowadzenie badania pilota˝owego dla opracowania optymalnego sposobu identyfikacji i oceny war-
toÊci diagnostycznej w´z∏ów wartowniczych w grupie chorych na raka p∏askonab∏onkowego sromu.
M a t e r i a ∏  i m e t o d a.  Do badania zakwalifikowano chore na raka p∏askonab∏onkowego sromu w stopniach zaawanso-
wania T1-2, N02, M0, u których wykonywano radykalne usuni´cie sromu. W´ze∏ wartowniczy identyfikowano Êródoperacyj-
nie przy pomocy gamma kamery po wczeÊniejszym podaniu izotopu technet 99m oraz na podstawie ich wybarwienia po poda-
niu barwnika Patentblau V.
W y n i k i.  We wszystkich tkankach przes∏anych do badania histopatologicznego jako w´z∏y ch∏onne odnaleziono utkanie ch∏on-
ne. Pozytywna wartoÊç prognostyczna stosowania obu metod identyfikacji w´z∏a wartowniczego wynosi 94.8%. Przerzuty do
w´z∏ów ch∏onnych stwierdzono w 13 na 40 operowanych pachwin. U 3 chorych stwierdzono przerzuty w w´z∏ach wartowni-
Departement of Gynaecological Oncology
The Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Warsaw, Poland
271
Introduction
In Poland about 200 patients each year die of vulvar
cancer [1]. The majority of these deaths are caused by
advanced cancer (stages III and IV, i.e. with the presence
of lymph node metastases) [2]. What is more, treatment
results are poor. This particular malignancy usually affects
women over 60 years of age [3], a majority of whom are
seriously compromised by other diseases, such as coronary
heart disease, arterial hypertension and diabetes. The
present standard in the treatment of vulvar cancer at our
institution is to perform a radical surgical excision of the
vulva with bilateral inguinal lymphadenectomy. The actual
stage of the disease, which should dictate the choice of
treatment protocol, is in fact assessed during postopera-
tive histopathological evaluation of the surgical specimen.
If routine hematoxylin/eosin staining of the tissue samples
reveals metastases to the inguinal lymph nodes the patient
is referred for radiotherapy of the pelvis encompassing
the inguinal lymph-node fields. However, surgical treat-
ment consists of a wide excision performed in a micro-
biologically comprised field (the vulva being a potentially
infected area) and often leads to septic complications.
These, in turn, delay recovery and, especially in patients of
an advanced age and in poor biological condition with
a number of co-existent diseases, significanly increase
postoperative mortality. On average the patients remain
in hospital for a period between 2 and 6 weeks. This
delays the onset of adjuvant treatment – which is in fact
a crucial element of the entire therapy when lymph node
metastases are present – seriously affecting the patients’
five-year survival results. On the other hand, lympha-
denectomy, when performed unnecessarily in patients
with no lymph node metastases, distinctly affects the
efficacy of the immune system thus, causing repercussions
which are difficult to foresee. In view of all this it is very
important to assess the actual stage of vulvar cancer with
the aid of the least invasive methods. Such evaluation
will, on the one hand, save a number of patients from
the handicap of unnecessary lymphadenectomy and, on
the other, will speed up the onset of adjuvant radiation
therapy.
Study aim
The aim of our study was to design and introduce an
optimal method of sentinel lymph node identification in
patients with stage I and II squamous cell carcinoma of
the vulva and to assess the diagnostic value of sentinel
lymph node biopsy in this particular malignancy.
Material and methods
The material consisted of consecutive patients treated at
the Department of Gynaecological Oncology of the Maria
Sklodowska-Curie Memorial Cancer Center in Warsaw
(MSCMCC) between January 1st 2001 and April 30th 2002 who
fulfilled the following criteria:
– WHO (Zubrod) overall performance status I-II.
– Histopathologically confirmed invasive squamous cell
carcinoma of the vulva.
– Clinical advancement stage T1-2, N0-2, M0.
– No history of previous treatment for either vulvar cancer
nor any other malignancy.
– Informed consent submitted in writing.
If all the above criteria were fulfilled the patients would
undergo thourough medical examination and a number of
additional diagnostic investigations including chest X-ray and
abdominal ultrasound (which are a part of routine before
oncological surgery at the MSCMCC) before final qualification.
All patients enrolled into the study were administered
Tc99m isotope of Technetium (activity 1.2 mCi) in the direct
viccinity of the vulvar tumour 24 hrs. before surgery. One hour
after isotope administration we performed a scintigraphic
examination of the inguinal lymph nodes in order to assess the
areas of isotope accumulation. Scintigraphy was performed with
a double-headed high-resolve VARICAM gamma-camera
(manufactured by ELSCINT), with a low-energy collimator.
The data was registered on a 256 x 256 matrix, zoom 1, over
a time of 10 minutes (aprox. 100 000 counts from each head).
The injection site was covered with leaden shielding (0.5 cm
thick). EXPERT software, by ELSCINT, was used for the
processing of results and figures.
All patients were operated by a team of specialists from the
Department of Gynecological Oncology of the MSCMCC. In
order to visualise the sentinel lymph node a 2.5% solution of
Patentbalu V was injected transcutaneously in the direct viccinity
of the vulvar tumour 10 minutes before skin excision. Inguinal
lymph node excision was performed as the first step of the
procedure. The sentinel nodes were identfied with a hand-held
gamma-camera equipped with a radiation meter (Navigator
GPS – Gamma Positioning System) in the following sequence of
measurements: (1) above the skin of the inguinal area, (2) after
skin incision identifying the sentinel nodes “in vivo”. After the
removal of the sentinels (either one or multiple nodes over
which we detected the highest isotope accumulation) the
radioactivity of the wound itself was measured and noted as the
so-called “background uptake”. If no isotope accumulation was
detected within the entire inguinal node area the nodes which
were stained with Patentblau V dye were removed and referred
for histopathological examination as the sentinels. Surgery was
continued with radical excision of the entire group of inguinal
lymph nodes and the vulva, in accordance with the present
MSCMCC standards of treatment of T1-2, N 0-2, M 0 squamous
carcinoma of the vulva.
All tissue specimens underwent histopathological evalua-
tion with routine hematoxylin/eosin staining and immunohisto-
chemical evaluation aimed at discerning the presence of
cytokeratines within the cancer cells. The sentinel lymph nodes
were examined independently from the remaining lymph nodes.
czych, natomiast nie stwierdzono ich w pozosta∏ych w´z∏ach ch∏onnych. Nie stwierdzono przypadku znalezienia przerzutów
w w´z∏ach pachwinowych i jednoczeÊnie nieobecnoÊci przerzutów w w´z∏ach wartowniczych.
W n i o s k i.  Wydaje si´, ˝e metoda limfoscyntygrafii i barwienia w´z∏ów barwnikiem Patentblau jest skuteczna w identyfikacji
w´z∏a wartowniczego. W celu oceny wartoÊci diagnostycznej w´z∏a wartowniczego konieczne jest przeprowadzenie badania na
wi´kszej liczbie chorych i d∏u˝sza obserwacja chorych po leczeniu.
Key words: vulvar cancer, sentinel node, lymphoscintigraphy
S∏owa kluczowe: rak sromu, w´ze∏ wartowniczy, limfoscyntygrafia
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Results
Between January 1st 2001 and April 30th 2002 36 women
were treated for vulvar carcinoma at the Department of
Gynaecological Oncology of the MSCMCC in Warsaw. Of
these 36 patients 20 fulfilled the criteria necessary to
enter the study. Data analysis has allowed us to come up
with the following results:
1. Gamma-camera examination and staining with
Patentblau V dye both allow to localise lymph nodes,
because all the specimens identified as such were
proven to contain lymphatic tissue
2. Gamma-camera examination has allowed for
sentinel lymph node identification in 36 cases (90%)
of a total of 40 excised inguinal basins. The positive
porognostic value of this method was 93.7%, while its
negative prognostic value was 94.1%. The sensitivity
and specificity of this method set at 97.9% and
88.2%, respectively.
3. Intraoperative evaluation established 34 cases of
Patentblau V-stained lymph nodes (85%) in a total of
40 excised inguinal basins. The positive prognostic
value of Patentblau V-staining was 96%, while its
negative prognostic value was 96.7%. The sensitivity
and specificity of this method set at 86.9% and
78.6%, respectively.
4. The positive prognostic value of both the methods
combined was 94.8%, while their negative prognostic
value was 95.4%. Their combined sensitivity and
specificity set at 92.4% and 83.4%, respectively.
5. Among the 20 studied patients inguinal lymph node
metastases were found in 11 cases; in 9 patients they
were bilateral, in the remaining 2 patients they were
limited to one side.
6. In 10 (25%) of the 40 excised inguinal basins
metastases were found both in the sentinel
lymphnodes and within the other unilateral nodes.
7. In 3 cases (7.5%) metastases were found in the
sentinel lymph nodes, while the remaining unilateral
inguinal nodes were metastases-free.
8. In no case of metastatic cancer found within the
inguinal nodes were the sentinel lymph nodes free of
metastases i.e. if we found metastatic cancer within
the nodes of one inguinal basin, then metastases
were always present also in the sentinel nodes.
9. No complications or side-effects of the sentinel
lymph node identification procedures were observed.
Discussion
The sentinel lymph node is defined as the first lymph
mode reached by the lymph flowing in from the drainage
area in which the tumour is located. In 1992 Morton
reported a technique for sentinel lymph node identifica-
tion in patients with melanoma of the skin [4]. Since then
numerous studies had been conducted in order to assess
whether the results of histopathological examination of
the sentinel lymph node are representative in comparison
to the state of other lymph nodes of the same basin. The
applicability of this method in malignancies other than
melanoma of the skin, for example in breast cancer [5]
was another widely studied issue. There is also extensive
research aimed at assessing the diagnostic value of
sentinel lymph node biopsy in patients treated for vulvar
cancer. One goal is to develop an optimal method of
sentinel lymph node identification. The other is to
evaluate whether sentinel lymph node biopsy may be
considered representative in cases of vulvar carcinoma.
As far as sentinel lymph node identification is
concerned two procedures are being recommended – one
is staining with injected dye – for example with Patentblau
V. The main assets of this method are: relatively low cost
(one 2 ml vial is an adequate dose for one patient), safety
(there are no reports of life-threatening side-effects) and
simplicity. The drawback of lymph node staining is that it
requires very precise timing – i.e. exact synchronisation
between administering the dye intracutaneously in the
direct viccinity of the tumour and visualising the sentinel
lymph node during surgery exactly 10 minutes after the
injection. If intraoperative visualisation is in any way
delayed the dye will reach further structures of the
lympatic system and render sentinel lymph node
identification not only difficult, but sometimes even
impossible. Levenback maintains that this method is cost-
effective and specific, while its sensitivity increases with
acquired practice [6, 7, 8]. The other sentinel lymph node
identification technique is that of measuring the radio-
activity of Technetium Tc99m isotope over the lymph
nodes. Lymphoscintigraphy is a diagnostic tool which has
been known for years, but which was to a certain extent
forsaken due to the development of computerised tomo-
graphy, magnetic resonance imaging and ultrasonography.
The last few years, however, have seen its rebirth, brought
on by the appearance of the gamma-camera, which allows
to measure the radioactivity of the isotope directly over
the lymphatic nodes. The isotopes which are currently in
use carry no risk for the patient, but their injection is
rather painful. In cases of vulvar cancer there were some
minor changes in the procedure. It had been presumed
that the isotope should be injected into the tumour, but it
has been proven that its administration in the direct
viccinity of the tumour is just as effective. A significant
limitation of this method is obtaining the gamma-camera
itself, the value of which on the Polish market is estimated
at 80 000-100 000 PLN. Nevertheless, the combination
of both these methods allows to increase the sensitivity of
sentinel lymph node identification. This aspect has been
stressed by many authors [9, 10, 11] and is also a finding
of our pilot study. Within the inguinal basins, which we
have examined, the lack of sentinel node staining was
observed more often (6 cases) than the lack of discernible
isotope activity (4 cases). At the same time in two cases
the lymph node identified as the sentinel was identified by
staining only, as no radioactivity was discerned over it.
In these two particular cases both the sentinel lymph
nodes and the other nodes of the inguinal basin were
free of metastases. It must be stressed, that the ability to
identify the sentinel node is only one aspect of this issue.
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A crucial query, which is still to be resolved, is the
diagnostic value of the sentinel lymph node biopsy. There
is a lot of data to prove that in cases where no metastases
are found within the sentinel lymph node the entire
inguinal basin may be considered free of vulvar cancer
metastases [12, 13, 14]. The pilot study which we have
performed supports these findings. In all those cases
where the lymph node identified as the sentinel was free
of metastases so where the remaining nodes removed in
the course of inguinal lymphadenectomy. In view of such
findings one may hope that sentinel lymph node biopsy
will, in the near future, allow to limit the extension of
lymph node excision in the surgical treatment of patients
with vulvar cancer. Numerous literature reports have
shown that early adjuvant chemo-radiotherapy plays
a crucial part in increasing five-year survivals of patients
treated for vulvar cancer. On the other hand, surgical
wounds after extensive inguinal lymphadenectomies are
difficult to heal. The hospitalisation period often extends
to six weeks. Even if one ignores the sheer economical
aspects of such long hospital stays, there remains the
most important issue – the delay in the onset of adjuvant
treatment, which puts both the patients’ health and their
lives at stake. At the same time, lymphadenectomies
performed unnecessarily, in patients with no metastases,
do nothing to increase the efficacy of oncological treat-
ment. In fact they only increase the patients’ handicap.
The issue is not only that of unnecessary human suffering
brough on by needless surgery – there are also other
consequences to consider. After inguinal lymphadenec-
tomy numerous complications are observed – oedema of
the lower extremities, limited movement and different
kinds of pain, including paraesthesia. It must also be
stressed that we do not no the consequences of destroying
an entire level of the lymphatic system on the immuno-
logical competence of the human organism. The mean
number of lymph nodes which we have removed in the
course of inguinal lympadectomies was 6 in the right basin
and 5 in the left basin (sentinels and unilateral lymph
nodes). The largest number of excised nodes was 14, the
smallest – 2 (one sentinel and one “ordinary” inguinal
lymph node). This lowest number of excised nodes was
observed only in 2 cases of a total of 40 inguinal
lymphadenectomies. In one of these two particular cases
the sentinel node contained metastatses, while the other
node was cancer-free. In the other case both the nodes
were free of cancer metastases. Due to the use of the
hand-held Neoprobe gamma-camera the site of the nodes
could be determined with great precision, which allowed
to perform a small skin incision and, thus, a much smaller
wound. In the course of this novel approach we also
observed improved healing of the inguinal wounds, thus
shortening the hospital stay. The mean duration of
postoperative hospitalisation was 16.7 days, which is
shorter than the hospital stays reported by other authors
(up to 6 weeks) [2].
Through limiting the extent of surgical excision it
was possible to reduce the frequency of typical complica-
tions to a significant extent. Under such circumstances
adjuvant treatment could be introduced much sooner
and, in due course, greatly improve the five-year survival
ratio.
Conclusions
Lymphoscintigraphy and Patentblau V staining have been
proven to be an efficient tool in the localisation of sentinel
lymph nodes in patients with vulvar cancer. No false
negative results of sentinel lymph node biopsies were
observed. Conclusions affecting the routine tactics of
vulvar cancer treatment can only be made after an
analysis of a larger study group. Moreover, both local
recurrence and/or the appearance of distant metastases
can only be assessed after at least 3 years of follow-up. It
has been established that in this particular group of
patients recurrence is usually observed during the first 2
years after radical treatment completion. At the same
time one cannot avoid raising questions as to the nature
of the mechanisms behind this particular malignancy,
especially in view of the fact that recurrences are observed
in cases of initial early advancement and after radical
treatment. Determining possible correlation between the
frequency of local recurrence or appearance of distant
metastases and the presence of micrometastases within
Table I. Evaluation of the sensitivity and specificity of Patentblau V staining and Tc99m 
lymphoscintigraphy for sentinel lymph node identification
Identification No. of Positive Negative Sensitivity Specificity
method positive prognostic prognostic
localisations value value
[%]
Staining 34/40 96% 96.7% 86.9% 78.6%
[85%]
Gamma-camera 36/40 93.7% 94.1% 97.9% 88.2%
[90%]
Staining – 94.8% 95.4% 92.4% 83.4%
& Gamma-camera
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both the sentinels and other lymph nodes, might help to
answer these important questions. It could also help to re-
assess the true value of the present-day treatment
regimes.
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